For cancers such as TNBC, where no particular “disease defining” SNVs exists other than non-specific TP53 mutations, a capture based or low-pass whole genome sequencing approach may be the better approach for ctDNA detection as they provide data on copy number changes and large structural rearrangements36. This evidence concerns the gene TP53 and cancer.